Destination Wealth Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Destination Wealth Management’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,483	Closed	-$117K	–	695
2019 Q1	$117K	Hold	1,483	–	–	0.01%	177
2018 Q4	$41K	Hold	1,483	–	–	﹤0.01%	278
2018 Q3	$74K	Buy	+1,483	New	+$76.5K	﹤0.01%	239
2018 Q2	–	Sell	-1,483	Closed	-$62K	–	606
2018 Q1	$62K	Hold	1,483	–	–	﹤0.01%	231
2017 Q4	$138K	Hold	1,483	–	–	0.01%	151
2017 Q3	$224K	Hold	1,483	–	–	0.01%	142
2017 Q2	$154K	Hold	1,483	–	–	0.01%	151
2017 Q1	$176K	Hold	1,483	–	–	0.01%	155
2016 Q4	$209K	Hold	1,483	–	–	0.02%	160
2016 Q3	$149K	Buy	1,483 +448	+43%	+$36.2K	0.01%	159
2016 Q2	$74K	Buy	+1,035	New	+$96.7K	0.01%	146

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

MHP

Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Destination Wealth Management's IMDX Position: Q2 2019 in Review

Destination Wealth Management sold out of Insight Molecular Diagnostics (IMDX) in Q2 2019, closing a stake of 1,483 shares — an estimated $117K sold.

Destination Wealth Management first reported a position in IMDX in Q2 2016 and held it in 11 quarters. The position peaked at $224K in Q3 2017. 54 funds tracked by Wall St. Rank hold IMDX as of Q2 2019.

Destination Wealth Management reported no remaining Insight Molecular Diagnostics position as of Q2 2019 after selling out during the quarter.
Destination Wealth Management sold 1,483 Insight Molecular Diagnostics shares in Q2 2019, an estimated $117K.
Destination Wealth Management first reported a position in Insight Molecular Diagnostics in Q2 2016 and held it in 11 quarters.
Destination Wealth Management's Insight Molecular Diagnostics position peaked at $224K in Q3 2017.
54 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2019.

Based on Destination Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.